Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2021 06:30 ET | Quelle: Affimed N.V.

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced...
10. März 2021 17:22 ET | Quelle: Affimed N.V.

Affimed Announces Presentations at the AACR Annual Meeting 2021

AFM24 preclinical in vivo data will be presented as a posterData on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 –...
10. März 2021 06:30 ET | Quelle: Affimed N.V.

Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis

Study will continue and combine cohorts of CD30 high and CD30 low expressing PTCL based on assessment from Independent Review CommitteeObjective responses observed in heavily pretreated patients in...
03. Februar 2021 06:30 ET | Quelle: Affimed N.V.

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today...
15. Januar 2021 09:21 ET | Quelle: Affimed N.V.

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate...
13. Januar 2021 06:15 ET | Quelle: Affimed N.V.

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to...
12. Januar 2021 16:01 ET | Quelle: Affimed N.V.

Affimed Announces Proposed Public Offering of Common Shares

Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to...
11. Januar 2021 06:45 ET | Quelle: Affimed N.V.

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
11. Januar 2021 06:30 ET | Quelle: Affimed N.V.

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank

€10 million available at closing and up to €15 million available upon achievement of certain milestones Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage...
07. Januar 2021 06:30 ET | Quelle: Affimed N.V.

Affimed Announces Pipeline and Business Update

Continued progress for AFM13 and AFM24 clinical studiesStrengthened cash position provides anticipated runway into the first half of 2023 Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq:...

Vorherige Seite

Nächste Seite